The Patent Finder
DT

Dyne Therapeutics, Inc.

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

63 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.

The next term ends in Aug 2039. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2039
Next term end
7
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 13 to 20, 2026 · next Dec 13
  • 1 fee due Mar 19, 2027
    The maintenance fee for Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy (US 11,759,525) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
  • 4 fees due Apr 3 to 24, 2027 · next Apr 3
  • 3 fees due Jun 5 to 19, 2027 · next Jun 5
  • 1 fee due Aug 27, 2027
    The maintenance fee for Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy (US 11,911,484) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 1 fee due Sep 19, 2027
    The maintenance fee for Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy (US 11,931,421) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
  • 1 fee due Oct 30, 2027
    The maintenance fee for Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy (US 11,969,475) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 5 of the patents on this record were granted since Aug 21, 2026

What they patent

The largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,111,309A Method of Reducing Expression of DUX4 in a Muscle Cell by Administering an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide Targeting DUX4
In force
 · Medium confidence
In forceMedium confidence
US 11,168,141Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
 · Medium confidence
In forceMedium confidence
US 11,248,056Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
 · Medium confidence
In forceMedium confidence
US 11,286,305Complex Comprising Anti-Transferrin Receptor Antibody Covalently Linked to an Oligonucleotide That Targets DUX4 RNA
In force
 · Medium confidence
In forceMedium confidence
US 11,369,689Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
 · Medium confidence
In forceMedium confidence
US 11,390,682Methods of Intravenouisly Delivering Anti-Transferrin Antibody/Oligonucleotide Complexes to Subjects Having Muscular Dystrophy
In force
 · High confidence
In forceHigh confidence
US 11,497,815Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
 · Medium confidence
In forceMedium confidence
US 11,518,816Methods of Delivering an Oligonucleotide to a Subject Having Facioscapulohumeral Muscular Dystrophy
In force
 · High confidence
In forceHigh confidence
US 11,633,496Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
 · Low confidence
In forceLow confidence
US 11,795,233Muscle-Targeting Complex Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
In force
 · Medium confidence
In forceMedium confidence
10 of 63 patents shown.
Pro members see all 63.
Pro members: see all 63 patents
Also on record, not counted in the 63: 40 applications pending · 17 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited